Innovative treatments for severe uncontrolled chronic rhinosinusitis with nasal polyps

References

• Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:1–464. doi:10.4193/Rhin20.401.
   Web of Science ®Google Scholar
• Bachert C, Marple B, Schlosser RJ, et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020;6:86. doi:10.1038/s41572-020-00218-1.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Yoshikawa M, Asaka D, et al. Mucosal eosinophilia and recurrence of nasal polyps - new classification of chronic rhinosinusitis. Rhinology. 2011;49:392–396.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Shiozawa A, Ono N, et al. Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil. Laryngoscope. 2013;123:E1–9.
   PubMed Web of Science ®Google Scholar
• Brescia G, Marioni G, Franchella S, et al. Can a panel of clinical, laboratory, and pathological variables pinpoint patients with sinonasal polyposis at higher risk of recurrence after surgery? Am J Otolaryngol. 2015;36:554–558.
   PubMed Web of Science ®Google Scholar
• Grgić MV, Ćupić H, Kalogjera L, et al. Surgical treatment for nasal polyposis: predictors of outcome. Eur Arch Otorhinolaryngol. 2015;272:3735–3743.
   PubMed Web of Science ®Google Scholar
• Lou H, Meng Y, Piao Y, et al. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population. Am J Rhinol Allergy. 2015;29:350–356.
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Sakashita M, Haruna T, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015;70:995–1003.
   PubMed Web of Science ®Google Scholar
• Brescia G, Marioni G, Franchella S, et al. A prospective investigation of predictive parameters for post-surgical recurrences in sinonasal polyposis. Eur Arch Otorhinolaryngol. 2016;273:655–660.
   PubMed Web of Science ®Google Scholar
• DeConde AS, Mace JC, Levy JM, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127:550–555.
   PubMed Web of Science ®Google Scholar
• Calus L, Van Bruaene N, Bosteels C, et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clin Transl Allergy. 2019;9:30.
   PubMed Web of Science ®Google Scholar
• Veloso-Teles R, Cerejeira R. Endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps: clinical outcome and predictive factors of recurrence. Am J Rhinol Allergy. 2017;31:56–62.
   PubMed Web of Science ®Google Scholar
• Saratziotis A, Emanuelli E, Zanotti C, et al. Endoscopic sinus surgery outcomes in CRS: quality of life and correlations with NOSE scale in a prospective cohort study. Eur Arch Otorhinolaryngol. 2021;278:1059–1066.
   PubMed Web of Science ®Google Scholar
• Vlaminck S, Vauterin T, Hellings PW, et al. The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study. Am J Rhinol Allergy. 2014;28:260–264.
   PubMed Web of Science ®Google Scholar
• Vlaminck S, Acke F, Prokopakis E, et al. Surgery in nasal polyp patients: outcome after a minimum observation of 10 years. Am J Rhinol Allergy. 2020;35:449–457.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131:1479–1490.
   PubMed Web of Science ®Google Scholar
• Cardell L-O, Stjarne P, Jonstam K, et al. Endotypes of chronic rhinosinusitis: impact on management. J Allergy Clin Immunol. 2020;145:752–756.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145:725–739.
   PubMed Web of Science ®Google Scholar
• Howarth P, Chupp G, Nelsen LM, et al. Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol. 2020;145:1713–1715.
   PubMed Web of Science ®Google Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449–1456.
   PubMed Web of Science ®Google Scholar
• Delemarre T, Holtappels G, De Ruyck N, et al. Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype. J Allergy Clin Immunol. 2020;146:337–343. doi:10.1016/j.jaci.2020.04.040.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147:29–36.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312–2319.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Hopkins C, et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology. 2020;58:82–111.
   PubMedGoogle Scholar
• Karin J, Tim D, Gabriele H, et al. Type 2 inflammatory shift in chronic rhinosinusitis during 2007-2018 in Belgium. Laryngoscope. 2020;131:1408–1414.
   Web of Science ®Google Scholar
• Gevaert E, Delemarre T, De Volder J, et al. Charcot-Leyden crystals promote neutrophilic inflammation in patients with nasal polyposis. J Allergy Clin Immunol. 2020;145:427–430.
   PubMed Web of Science ®Google Scholar
• Aoki A, Hirahara K, Kiuchi M, et al. Eosinophils: cells known for over 140 years with broad and new functions. Allergol Int. 2021;70:3–8.
   PubMed Web of Science ®Google Scholar
• Scott G, Asrat S, Allinne J, et al. IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline. Cytokine. 2023;162:156091.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Arkwright PD, Bruggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75:1582–1605.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Hirahara K, Onodera A, et al. Th2 cells in health and disease. Ann Rev Immunol. 2017 In: Littman DR, Yokoyama WM, editors;35:53–84.doi: 10.1146/annurev-immunol-051116-052350
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673–680.
   PubMed Web of Science ®Google Scholar
• Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol Res. 2017;9:299–306.
   PubMed Web of Science ®Google Scholar
• Wang C, Yan B, Zhang L. The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol. 2020;16:293–310. doi:10.1080/1744666X.2020.1723417.
   PubMed Web of Science ®Google Scholar
• Stein M, Keshav S, Harris N, et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287–292.
   PubMed Web of Science ®Google Scholar
• Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604.
   PubMed Web of Science ®Google Scholar
• Van Zele T, Gevaert P, Holtappels G, et al. Local immunoglobulin production in nasal polyposis is modulated by superantigens. Clin Exp Allergy. 2007;37:1840–1847.
   PubMed Web of Science ®Google Scholar
• Lan F, Zhang N, Holtappels G, et al. Staphylococcus aureus induces a mucosal type 2 immune response via epithelial cell-derived cytokines. Am J Respir Crit Care Med. 2018;198:452–463. doi:10.1164/rccm.201710-2112OC.
   PubMed Web of Science ®Google Scholar
• Valera FCP, Ruffin M, Adam D, et al. Staphylococcus aureus impairs sinonasal epithelial repair: effects in patients with chronic rhinosinusitis with nasal polyps and control subjects. J Allergy Clin Immunol. 2019;143:591–603.
   PubMed Web of Science ®Google Scholar
• Bachert C, Humbert M, Hanania NA, et al. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. Eur Respir J. 2020;55:55.
   Web of Science ®Google Scholar
• Hayes SM, Biggs TC, Goldie SP, et al. Staphylococcus aureus internalization in mast cells in nasal polyps: characterization of interactions and potential mechanisms. J Allergy Clin Immunol. 2020;145:147–159.
   PubMed Web of Science ®Google Scholar
• Baba S, Kondo K, Toma-Hirano M, et al. Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis. Clin Exp Allergy. 2014;44:701–712.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Nouri-Aria KT, Wu H, et al. Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy. 2013;68:55–63.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650. doi:10.1016/S0140-6736(19)31881-1.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146:595–605.
   PubMed Web of Science ®Google Scholar
• Yang SK, Cho SH, Kim DW. Interpretation of clinical efficacy of biologics in chronic rhinosinusitis with nasal polyps via understanding the local and systemic pathomechanisms. Allergy Asthma Immunol Res. 2022;14:465–478.
   PubMed Web of Science ®Google Scholar
• Delemarre T, Bochner BS, Simon HU, et al. Rethinking neutrophils and eosinophils in chronic rhinosinusitis. J Allergy Clin Immunol. 2021;148:327–335.
   PubMed Web of Science ®Google Scholar
• Stevens WW, Peters AT, Tan BK, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7:2812–2820.
   PubMed Web of Science ®Google Scholar
• Tan BK, Klingler AI, Poposki JA, et al. Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol. 2017;139:699–703.
   PubMed Web of Science ®Google Scholar
• Van Zele T, Holtappels G, Gevaert P, et al. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28:192–198.
   PubMed Web of Science ®Google Scholar
• Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol. 2008;122:961–968.
   PubMed Web of Science ®Google Scholar
• Zhang N, Holtappels G, Claeys C, et al. Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps from southern China. Am J Rhinol. 2006;20:445–450.
   PubMedGoogle Scholar
• Huang Y, Zhang N, Xu Z, et al. The development of the mucosal concept in chronic rhinosinusitis and its clinical implications. J Allergy Clin Immunol Pract. 2022;10:707–715. doi:10.1016/j.jaip.2021.10.054.
   PubMed Web of Science ®Google Scholar
• Alsharif S, Jonstam K, van Zele T, et al. Endoscopic sinus surgery for type-2 CRS wNP: an endotype-based retrospective study. Laryngoscope. 2019;129:1286–1292.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhang N, Huang Y, et al. Is surgery for severe type 2 nasal polyps safe under the treatment with biologics? Annals of Allergy, Asthma & Immunol. 2022;128:328–330.
   PubMed Web of Science ®Google Scholar
• Gomes SC, Delemarre T, Holtappels G, et al. Olfaction in nasal polyp patients after Reboot surgery: an endotype-based prospective study. Eur Arch Otorhinolaryngol. 2022:1–10. DOI:10.1007/s00405-022-07813-w.
   PubMed Web of Science ®Google Scholar
• Moreno-Luna R, Martin-Jimenez DI, Callejon-Leblic MA, et al. Usefulness of bilateral mucoplasty plus reboot surgery in severe type-2 chronic rhinosinusitis with nasal polyps. Rhinology. 2022;60:368–376.
   PubMed Web of Science ®Google Scholar
• Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:1141–1153.
   PubMed Web of Science ®Google Scholar
• Bachert C, Sousa AR, Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol. 2022;149:1711–1721.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Boyle RJ. Mepolizumab for eosinophilic chronic rhinosinusitis, loss of smell and challenges with accessibility to allergen immunotherapy. Clin Exp Allergy. 2022;52:1358–1360.
   PubMed Web of Science ®Google Scholar
• Walter S, Ho J, Alvarado R, et al. Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis. Clin Exp Allergy. 2022;52:1403–1413.
   PubMed Web of Science ®Google Scholar
• Buchheit KM, Lewis E, Gakpo D, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;148:574–584.
   PubMed Web of Science ®Google Scholar
• Cavaliere C, Masieri S, Greco A, et al. Nasal expression of the vascular endothelial growth factor and its receptors is reduced by mepolizumab in chronic rhinosinusitis with nasal polyposis. Annals of Allergy, Asthma & Immunol. 2021;126:442–443.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118:1133–1141.
   PubMed Web of Science ®Google Scholar
• Weinstein SF, Katial RK, Bardin P, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2019;7:589–596.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2021;149:1309–1317.
   PubMed Web of Science ®Google Scholar
• Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51:836–844.
   PubMed Web of Science ®Google Scholar
• Maza-Solano J, Calvo-Henriquez C, Alobid I, et al. Nasal symptoms in asthmatic patients under treatment with anti-IL-5 monoclonal antibodies. A real-life cohort study. J Clin Med. 2022;11:7056.
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Bachert C, Amin N, et al. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Annals of Allergy, Asthma & Immunol. 2021;126:584–592.
   PubMed Web of Science ®Google Scholar
• Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology. 2021;59:301–311.
   PubMed Web of Science ®Google Scholar
• Jonstam K, Swanson BN, Mannent LP, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019;74:743–752.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10:2695–2709.
   PubMed Web of Science ®Google Scholar
• Bachert C, Corren J, Lee SE, et al. Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials. Int Forum Allergy Rhinol. 2022;12:1191–1195.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Saenz R, Corren J, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol. 2021;149:957–965.
   PubMed Web of Science ®Google Scholar
• Han JK, Yoo B, Saenz R, et al. Omalizumab and quality of life in nasal polyps: a post hoc analysis. Int Forum Allergy Rhinol. 2022;12:1188–1190.
   PubMed Web of Science ®Google Scholar
• Wangberg H, Spierling Bagsic SR, Osuna L, et al. Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2021;10:478–484.
   PubMed Web of Science ®Google Scholar
• Peters AT, Han JK, Hellings P, et al. Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;9:2461–2471.
   PubMed Web of Science ®Google Scholar
• Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol. 2021;149:1286–1295. doi:10.1016/j.jaci.2021.09.009.
   PubMedGoogle Scholar
• Cai S, Xu S, Lou H, et al. Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis. J Allergy Clin Immunol Pract. 2022;10:1876–1886.
   PubMed Web of Science ®Google Scholar
• Mummler C, Dunzelmann K, Kneidinger N, et al. Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin Transl Allergy. 2021;11:e12049.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Chan R. The choice of biologics in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;9:4235–4238.
   PubMed Web of Science ®Google Scholar
• Barroso B, Valverde-Monge M, Alobid I, et al. Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study. J Investig Allergol Clin Immunol. 2022;33:37–44.
   PubMedGoogle Scholar
• Haxel BR, Hummel T, Fruth K, et al. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology. 2022;60:435–443.
   PubMed Web of Science ®Google Scholar